| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.36 | 6e-32 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.42 | 1e-21 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.28 | 2e-16 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.27 | 6e-16 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.24 | 3e-12 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.2 | 2e-11 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | 0.21 | 1e-10 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.32 | 4e-10 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.22 | 5e-10 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.29 | 4e-09 |